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Background: Poria cocos Wolf, a medicinal fungus, is widely used in traditional medicines in East Asian countries
owing to its various therapeutic potentials. Although several studies have demonstrated the anti-inflammatory
activity of this fungus, its underlying mechanisms have not yet been clearly defined.
Methods: In the present study, we have demonstrated the anti-inflammatory effects of ethanol extract of P. cocos
(EEPC) in lipopolysaccaride (LPS)-stimulated RAW 264.7 macrophages. As inflammatory parameters, the productions
of nitric oxide (NO), prostaglandin E2 (PGE2), interleukin (IL)-1β and tumor necrosis factor (TNF)-α were evaluated.
We also examined the EEPC’s effect on the nuclear factor-kappaB (NF-κB) signaling pathway.
Results: Our results indicated that EEPC exhibits a potent inhibitory effect on NO production and inhibits PGE2
release in LPS-induced macrophages without affecting cell viability. EEPC also significantly attenuated LPS-induced
secretion of inflammatory cytokines IL-1β and TNF-α. Additionally, LPS-induced expression of inducible NO synthase
(iNOS), cyclooxygenase (COX)-2, IL-1β, and TNF-α was decreased by pre-treatment with EEPC at the transcriptional
level. Moreover, EEPC clearly inhibited LPS-induced nuclear translocation of NF-κB p65 subunits, which correlated
with EEPC’s inhibitory effects on inhibitor kappaB (IκB) degradation. Moreover, EEPC clearly suppressed the
LPS-induced DNA-binding activity of NF-κB, as well as the nuclear translocation of the NF-κB p65, which correlated
with EEPC’s inhibitory effects on inhibitor kappaB (IκB) degradation.
Conclusions: Taken together, our data indicates that EEPC targets the inflammatory response of macrophages
via inhibition of iNOS, COX-2, IL-1β, and TNF-α through inactivation of the NF-κB signaling pathway, supporting
the pharmacological basis of P. cocos as a traditional herbal medicine for treatment of inflammation and its
associated disorders.
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Inflammation is an essential aspect of the host’s response
to infection and injury caused by invading pathogens to
maintain a healthy state. However, excessive or aberrant in-
flammation leads to the up-regulation of several kinds of
pro-inflammatory enzymes such as nitric oxide synthase
(NOS) and cyclooxygenase (COX) as mediators of inflam-
mation in affected inflammatory cells, which contribute
to many acute and chronic human diseases [1,2]. NOSs
are comprised of three members, including endothelial
NOS (eNOS), neuronal NOS (nNOS), and inducible NOS
(iNOS), which makes NO from L-arginine, and COX exists
as two isozymes, COX-1 and COX-2, converting arachi-
donic acid into prostaglandins (PGs). Among them, iNOS
and COX-2 are highly expressed in response to inflamma-
tory inducers, and are responsible for the production of a
huge amount of NO and prostaglandin E2 (PGE2), respect-
ively [3,4]. The inflammatory response is also well charac-
terized by the abundant production of pro-inflammatory
cytokines, such as interleukin-1β (IL-1β) and tumor nec-
rotic factor-α (TNF-α). They are also mainly produced in
activated macrophages by inflammatory inducers. Over-
production of IL-1β increases the expression of adhesion
factors on endothelial cells to enable transmigration of
leukocytes, and is associated with hyperalgesia and fever
[5,6]. In particular, TNF-α is important for stimulating the
secretion of other inflammatory cytokines, which, in turn,
causes many clinical problems associated with autoimmune
disorders [7,8]. Key pro-inflammatory stimuli including
bacterial lipopolysaccharide (LPS), mitogens, and cytokines
modulate their effects by inducing the activation of nuclear
factor-kappaB (NF-κB), which regulates the expression
of many genes involved in immune and inflammatory
responses [9,10]. For this reason, inhibition of pro-
inflammatory mediators and cytokines by these NF-κB re-
sponse genes has been proposed to be a good approach
for the treatment of various inflammatory diseases [11,12].
Poria cocos Wolf is a medicinal mushroom in the Poly-
poraceae family that grows on the roots of old, dead pine
trees. The dried sclerotia of P. cocos has frequently been
used as a tonic to benefit the internal organs and is
prescribed as one of the chief ingredients in compound
prescriptions in traditional Oriental medicine [13-15]. In
particular, this fungus is widely used in traditional medicine
to treat chronic gastritis, acute gastroenteric catarrh, gastric
atony, oedema, nephrosis, dizziness, nausea, and emesis
[16,17]. Many previous studies have indicated that its ex-
tracts and components have a variety of biological activities
such as anti-fungal and anti-bacterial [18], antioxidant
[19-21], neuroprotective [22], anti-hypertonic [23], anti-
inflammatory [17,24-26], anti-angiogenic [27,28], and anti-
cancer effects [29,30]. However, the claimed benefits and
their action mechanisms are not fully understood. In this
study, as a part of our on-going screening program toevaluate the anti-inflammatory potentials of medicinal
mushrooms, we investigated the anti-inflammatory proper-
ties of an ethanol extract of P. cocos (EEPC) and the respon-
sible underlying molecular mechanisms involved in an
LPS-stimulated RAW 264.7 murine macrophage model.
We found that EEPC down-regulated the production of
pro-inflammatory mediators (NO and PGE2) as well as
pro-inflammatory cytokines (IL-1β and TNF-α) by sup-
pressing the NF-κB signaling pathway.
Methods
Materials
LPS, Griess reagent, Tween 20, 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulf-
oxide (DMSO), and 4,6-diamidino-2-phenyllindile (DAPI)
were purchased from Sigma-Aldrich Chemical Co. (St.
Louis, MO, USA). Antibodies against iNOS, COX-2, NF-κB
p65, inhibitor kappaB (IκB), nucleolin and actin were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). The peroxidase-labeled donkey anti-rabbit im-
munoglobulin, peroxidase-labeled sheep anti-mouse im-
munoglobulin and enhanced chemiluminescence (ECL)
detection kit were purchased from Amersham Corp.
(Arlington Heights, IL, USA). Dulbecco’s modified
Eagle’s minimum essential medium (DMEM) containing
l-glutamine (200 mg/L), fetal bovine serum (FBS), peni-
cillin, and streptomycin were obtained from Gibco-BRL
(Grand Island, NY, USA). The enzyme-linked immuno-
sorbent assay (ELISA) kits for PGE2, TNF-α, and IL-1β
were obtained from R&D Systems (Minneapolis, MN,
USA). COX-2, iNOS, TNF-α, IL-6, and GAPDH oligo-
nucleotide primers were purchased from Bioneer (Seoul,
Korea). Fluorescein isothiocyanate (FITC)-conjugated don-
key anti-rabbit IgG and Fluoromount-G were obtained
from Jackson ImmunoResearch Laboratories Inc. (West
Grove, PA, USA) and Southern Biotechnology Associates
Inc. (Birmingham, AL, USA), respectively. All other chemi-
cals were purchased from Sigma-Aldrich.
Preparation of the ethanol extract of P. cocos (EEPC)
The dried sclerotium of P. cocos were supplied by Dongeui
University Oriental Hospital (Busan, Republic of Korea)
and authenticated by Professor S.H. Hong, Department
of Biochemistry, Dongeui University College of Oriental
Medicine. A voucher specimen (accession number DEU-
24) was deposited at the Natural Resource Bank of Dongeui
University College of Oriental Medicine. To prepare the
EEPC, the dried sclerotium of P. cocos was ground into
powder and extracted twice with 10 volumes of 80% etha-
nol at 85-90˚C in a reflux condenser for 3 h. After being fil-
tered through a 0.2-μm filter, the extract was concentrated
and lyophilized by vacuum evaporation at 60˚C. The solid
form of the extract was dissolved in DMSO prior to the
experiment.
Jeong et al. BMC Complementary and Alternative Medicine 2014, 14:101 Page 3 of 8
http://www.biomedcentral.com/1472-6882/14/101Cell culture and MTT assay
The RAW 264.7 macrophage cell line was obtained from
American Type Culture Collections (Manassas, VA, USA)
and cultured at 37°C in 5% CO2 in DMEM medium sup-
plemented with 10% FBS, 100 units/ml penicillin, and
100 μg/ml streptomycin in the presence or absence of
EEPC. The cell viability was measured using a MTT assay.
Briefly, RAW 264.7 cells (5 × 105 cells/ml) were treated with
the indicated concentrations of EEPC or LPS (0.5 μg/ml)
alone, or pre-treated with different concentrations of EEPC
for 1 h before LPS treatment. After 24 h, the medium was
removed and the cells were incubated with 0.5 mg/ml of
MTT solution for 2 h. And then, the supernatant was dis-
carded and the formazan blue, which was formed in the
cells, was dissolved with DMSO. The optical density was
measured at 540 nm with a microplate reader (Dynatech
Laboratories, Chantilly VA, USA).
Nitrite determination
The nitrite accumulated in culture medium was measured
as an indicator of NO production based on the Griess re-
action. Briefly, 100 μl of cell culture medium was collected
at the end of culture, mixed with an equal volume of
Griess reagent, incubated at room temperature. After
10 min, the absorbance at 540 nm was measured using an
ELISA plate reader at 540 nm. The concentration of nitrite
was calculated from a standard curve drawn with known
concentrations of sodium nitrite dissolved in DMEM [31].
Determination of PGE2, TNF-α, and IL-1β production
RAW 264.7 macrophages were pre-treated with EEPC for
1 h and then stimulated with LPS (0.5 μg/ml) for 24 h.
PGE2, TNF-α, and IL-1β levels in macrophage culture
media were quantified using ELISA kits according to the
manufacturer’s instructions [32].
RNA isolation and reverse transcriptase polymerase chain
reaction (RT-PCR) assay
After the removal of supernatants from cells cultured in the
presence of EEPC alone or in combination with LPS for
24 h, total RNA was isolated using TRIzol reagent
(Invitrogen Co., Carlsbad, CA, USA) according to the man-
ufacturer’s instructions. From each sample, 2 μg of total
RNA was reverse transcribed to single-stranded cDNA by
M-MLV reverse transcriptase (Promega, Madison, WI).
Then PCR analyses were performed on the aliquots of the
cDNA preparations to detect COX-2, iNOS, TNF-α, and
IL-1β gene expression. The iNOS, COX-2, IL-1β, and TNF-
α genes were amplified from the cDNA using PCR. The
PCR primers were as follows: mouse iNOS (5′-ATG TCC
GAA GCA AAC ATC AC-3′ and 5′-TAA TGT CCA GGA
AGTAGG TG-3′), COX-2 (5′-CAG CAA ATC CTT GCT
GTT CC-3′ and 5′-TGG GCA AAG AAT GCA AAC
ATC-3′), IL-1β. (5′-ATG GCA ACT GTT CCT GAA CTCAAC T-3′ and 5′-TTT CCT TTC TTA GAT ATG GAC
AGG AC-3′), and TNF-α (5′-ATG AGC ACA GAA AGC
ATG ATC-3′ and 5′-TAC AGG CTT GTC ACT CGA
ATT-3′). After amplification, the PCR products were elec-
trophoresed in 1% agarose gels and visualized by ethidium
bromide (EtBr) staining and ultra violet (UV) irradiation. In
a parallel experiment, glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was used as an internal control.
Protein extraction and Western blot analysis
After 24 h treatment as described above, the total proteins
of RAW 264.7 cells were directly prepared in lysis buffer
(0.5% Triton, 50 mM β-glycerophosphate (pH 7.2), 0.1 mM
sodium vanadate, 2 mM MgCl2, 1 mM EGTA, 1 mM
dithiothreitol, 2 μg/mL leupeptin, 0.1 mM phenylmethyl-
sulfonyl urea, and 4 μg/mL aprotinin). In a parallel experi-
ment, nuclear and cytosloic proteins were prepared using
nuclear extraction reagents (Pierce, Rockford, IL, USA)
according to the manufacturer’s protocol. The protein con-
centration in the cell lysate was determined using detergent-
compatible protein assay from Bio-Rad (Hercules, CA,
USA). Equal amounts of protein were resolved by sodium
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis
and transferred to nitrocellulose membrane (Schleicher &
Schuell, Keene, NH, USA). Subsequently, the membranes
were blocked in Tris-buffered saline (10 mM Tris-Cl,
pH 7.4) containing 0.5% Tween 20 and 5% nonfat dry
milk for 1 h. After incubation with the appropriate primary
antibodies for 1 h, the membranes were incubated for 1 h at
room temperature with secondary antibodies conjugated to
horseradish peroxidase. The immunoreactive bands were
detected by ECL solution.
Electrophoretic mobility assay (EMSA)
EMSA was performed with the nuclear extract. Synthetic
complementary NF-κB (5′-AGT TGA GGG GAC TTT
CCC AGG C-3′) binding oligonucleotides (Santa Cruz Bio-
technology) were 3′-biotinylated using the biotin 3′-end
DNA labeling kit (Pierce) according to the manufacturer’s
instructions, and annealed for 30 min at room temperature.
Assays were loaded onto native 4% polyacrylamide gels
pre-electrophoresed for 60 min in 0.5× Tris borate/EDTA
before being transferred onto a positively charged nylon
membrane (HybondTM-N+) in 0.5 × Tris borate/EDTA at
100 V for 30 min. The transferred DNAs were cross-linked
to the membrane at 120 mJ/cm2. Horseradish peroxidase-
conjugated streptavidin was used according to the manu-
facturer’s instructions to detect the transferred DNA.
Immunofluorescence staining
The NF-κB p65 nuclear localization was detected by im-
munofluorescence assays using a fluorescence microscope.
For this study, RAW 264.7 cells were cultured directly on
glass coverslips in 24-well plates for 24 h. After stimulation
Figure 1 Inhibition of NO and PGE2 production by EEPC
pre-treatment in LPS-stimulated RAW 264.7 macrophages.
Cells were pre-treated with different concentrations of EEPC for
1 h, LPS (0.5 μg/mL) was then added, and cells were incubated for
24 h. The culture supernatants were subject to the nitrite assay
(A) and to a PGE2 immunoassay (B). Values represent the mean ±
SD of three independent experiments. We assessed differences
between mean values by the Student’s t-test. *P < 0.05 indicates
significant differences from the LPS-treated group.
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fixed with 4% paraformaldehyde in PBS, permeabilized with
0.2% triton X-100 in PBS, and blocked with 1.5% normal
donkey serum. Polyclonal antibodies against anti-NF-κB
p65 (1 μg/well) were applied for 1 h followed by an 1 h in-
cubation with FITC-conjugated donkey anti-rabbit IgG.
The position of the cell nucleus was determined with DAPI.
After washing with PBS, the coverslips were mounted in
Fluoromount-G, and the fluorescence was visualized using
a fluorescence microscope (Carl Zeiss, Germany) [33].
Statistical analysis
All values are presented as mean ± standard deviation (SD).
We assessed comparisons between groups by one-way ana-
lysis of variance (Dunnett’s t-test) and Student’s t-test. P
values ≤ 0.05 were considered statistically significant.
Results
EEPC inhibits LPS-induced NO and PGE2 production in
RAW 264.7 macrophages
RAW 264.7 cells were stimulated with LPS for 24 h after
being pre-treated with various concentrations of EEPC
for 1 h, and cell culture media were collected, and NO
levels were quantified initially using the Griess reaction.
As shown in Figure 1A, when LPS was added to RAW
264.7 cells, NO production was increased dramatically,
however, EEPC suppressed LPS-induced NO production
in a concentration-dependent manner. Moreover, the
PGE2 assay revealed that EEPC significantly attenuated
LPS-induced PGE2 production (Figure 1B).
EEPC down-regulates LPS-induced iNOS and COX-2
expression in RAW 264.7 macrophages
To determine the inhibitory mechanism of EEPC on
NO and PGE2 production from LPS-activated RAW
264.7 cells, we examined the expression levels of iNOS
and COX-2 protein and mRNA by Western blot and
RT-PCR analyses. In response to LPS, the protein levels
of iNOS and COX-2 were significantly induced; how-
ever, pre-treatment with EEPC dramatically inhibited
these up-regulations in a concentration-dependent man-
ner (Figure 2A). Furthermore, pre-treatment with EEPC
markedly suppressed mRNA expression of iNOS and
COX-2 in the same manner as for their protein expression
(Figure 2B). These results indicate that the reductions in
the expression of iNOS and COX-2 at the transcriptional
levels contributed to the inhibitory effect of EEPC on LPS-
induced NO and PGE2 production.
EEPC reduces the production of pro-inflammatory
cytokines in LPS-stimulated RAW 264.7 macrophages
Since EEPC was revealed as a potent inhibitor of the
pro-inflammatory mediators, we further investigated its
effect on pro-inflammatory cytokine release by ELISA.The results obtained showed that treatment of RAW 264.7
cells with LPS alone resulted in a significant increase in
production of IL-1β compared to that generated under
control conditions (Figure 3A). However, pre-treatment
with EEPC considerably inhibited LPS induction of IL-1β
in a concentration-dependent manner. Under these condi-
tions, pre-treatment with EEPC also reduced TNF-α pro-
duction dramatically (Figure 3B). Furthermore, the RT-PCR
results showed that non-activated or EEPC-alone treated
RAW 264.7 cells did not express any detectable levels of
IL-1β and TNF-α mRNA; however, EEPC significantly at-
tenuated LPS-induced mRNA levels of these cytokines
(Figure 4).
EEPC inhibits the nuclear translocation of NF-κB in
LPS-stimulated RAW 264.7 macrophages
To further characterize the mechanism underlying the
anti-inflammatory effects of EEPC, we assessed the NF-
κB signaling pathway, which is critical in the activation
of pro-inflammatory enzymes and cytokines. Immuno-
blotting results in Figure 5A showed that the amount of
Figure 2 Down-regulation of LPS-induced iNOS and COX-2
protein and mRNA expression by EEPC pre-treatment in RAW
264.7 macrophages. (A) Cells were pre-treated with different
concentrations of EEPC for 1 h, then with LPS (0.5 μg/ml), and
incubated for 24 h. Total cellular proteins (30 μg) were resolved by
SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose
membranes, and detected with anti-COX-2 and iNOS antibodies, and
an ECL detection system. (B) After LPS treatment for 6 h, total RNA was
prepared for the RT-PCR analysis of COX-2 and iNOS gene expression.
The amplified PCR products were run in a 1% agarose gel and visualized
by EtBr staining. Actin and GAPDH were used as internal controls for the
Western blot and RT-PCR assays, respectively.
Figure 3 Effects of EEPC on LPS-induced IL-1β and TNF-α
release in RAW 264.7 macrophages. Cells were pre-treated with
the indicated concentrations of EEPC 1 h prior to incubation with
LPS (0.5 μg/ml). After incubation for 24 h, the levels of IL-1β (A) and
TNF-α (B) present in the supernatants were measured using ELISA
kits. The values shown here are means ± SD of three independent
experiments. * P < 0.05 indicates a significant difference from the
value obtained for cells treated with LPS in the absence of EEPC.
Figure 4 Effects of EEPC on LPS-induced IL-1β and TNF-α
expression in RAW 264.7 macrophages. The cells were
pre-treated with various concentrations of EEPC for 1 h before LPS
treatment (0.5 μg/ml), and total RNA was isolated at 6 h after LPS
treatment. The levels of IL-1β and TNF-α mRNA were determined
using RT-PCR. GAPDH was used as an internal control.
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posure to LPS alone, concomitantly with a degradation
in IκB-α. However, pre-treatments with EEPC markedly
reduced the LPS-induced nuclear accumulation of NF-
κB p65. In parallel with the inhibitory effect of EEPC,
LPS-induced IκB-α degradation was obviously blocked
by pre-treatment with EEPC. EMSA also showed that
treatment with LPS causes an increase in NF-κB DNA-
binding activity at 30 min, while pretreatment of the
cells with EEPC for 1 h resulted in a significant reduc-
tion in the DNA-binding activity of NF-κB (Figure 5B).
In addition, the immunofluorescence images revealed
that NF-κB p65 was normally sequestered in the cyto-
plasm, and nuclear translocation of NF-κB p65 was not
observed in the cells after treatment with EEPC alone in
the absence of LPS stimulation (Figure 6). However, the
nuclear localization of NF-κB p65 in RAW 264.7 cells
was significantly induced after stimulation with LPS,
which was completely abolished after pre-treating the
cells with EEPC. The findings indicate that the inactiva-
tion of the NF-κB signaling pathway was involved in the
anti-inflammatory effect of EEPC in LPS-stimulated
RAW 264.7 cells.Effects of EEPC on the viability of RAW264.7 macrophages
To examine whether EEPC is cytotoxic to RAW 264.7
cells, the cells were exposed to various concentrations of
EEPC for 24 h in the presence or absence of LPS, and cell
viability was then measured by the MTT assay. Results
showed that, within our tested concentrations, no EEPC
cytotoxic effect was observed (Figure 7). These results
clearly indicated that the anti-inflammatory activity of
Figure 5 Inhibition of LPS-induced nuclear accumulation of
NF-κB p65 and degradation of IκB-α by EEPC pre-treatment in
RAW 264.7 macrophages. Cells were treated with 8 μg/ml EEPC
for 1 h before LPS treatment (0.5 μg/ml) for the indicated times.
(A) Nuclear and cytosolic proteins were subjected to 10%
SDS-polyacrylamide gels followed by Western blotting using
anti-NF-κB p65 and anti-IκB-α antibodies. Nucleolin and actin were
used as internal controls for the nuclear and cytosolic fractions,
respectively. (B) Cells were pre-incubated with EEPC 1 h before
stimulation with LPS for 30 min. Nuclear extracts were then assayed
for NF-κB activity by EMSA (N.S.; non specific).
Figure 6 Effects of EEPC on LPS-induced nuclear translocation
of NF-κB p65 in RAW 264.7 macrophages. Cells were pre-treated
with 8 μg/ml EEPC for 1 h, LPS (0.5 μg/mL) was then added, and cells
were incubated for 30 min. Localization of NF-κB p65 was visualized with
fluorescence microscopy after immunofluorescence staining with NF-κB
p65 antibody (green). Cells were stained with DAPI for visualization of
the nuclei (blue). A representative sample of three independent
experiments is shown.
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due to its cytotoxicity.Figure 7 Effect of EEPC on the cell viability of RAW 264.7
macrophages. Cells were treated with the various concentrations
of EEPC for 1 h and then the cells were stimulated with 0.5 μg/mL
LPS. After 24 h, cytotoxicity was determined by measuring the
absorbance at 450 nm after MTT reagent addition and the results
are expressed as the percentage of surviving cells over control cells
(no addition of EEPC and LPS). The values shown here are means ±
SD of three independent experiments.Discussion
Although the dried sclerotia of P. cocos, a well-known
medicinal fungus, is widely used in traditional Oriental
medicine owing to its multiple beneficial potentials, the
molecular targets and the mechanisms underlying its anti-
inflammatory activities are still unclear to date. Inhibitors
of pro-inflammatory mediators and cytokines have been
considered as candidates for anti-inflammatory agents. In
the present study, we first demonstrated that EEPC re-
duced LPS-induced NO and PGE2 production in RAW
264.7 macrophages through down-regulation of iNOS and
COX-2 at both the protein and mRNA levels, which sug-
gests that EEPC acts at the transcriptional level. EEPC also
reduced the LPS-induced production and mRNA expres-
sion of the pro-inflammatory cytokines, IL-1β and TNF-α.
Furthermore, these effects were not due to the cytotoxicity
of EEPC and were mediated through the inhibition of the
nuclear translocation of NF-κB.
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rophages, NO and PGE2 have been implicated as the main
cytotoxic mediators participating in the innate response in
mammals. Although NO generation by macrophages is a
part of the human immune response, activated macro-
phages following bacterial infection or inflammatory re-
sponses generate a large amount of NO from arginine and
oxygen through transcriptional activation of iNOS. Further-
more, excessive release of NO by activated macrophages is
correlated with the progression of inflammation-associated
disorders [2,34]. There is mounting evidence for the expres-
sion of COX-2, a key enzyme involved in the conversion of
arachidonic acid to PGE2, being up-regulated in activated
macrophages. In addition, the activation of COX-2 is asso-
ciated with cytotoxicity at the site of the inflammation,
because inhibition of COX-2 induction and/or activity re-
duces the progression of inflammatory disorders [1,3]. Thus,
down-regulators of these pro-inflammatory mediators
have been considered as potential candidates for anti-
inflammatory agents to alleviate the progression of inflam-
matory diseases such as atherosclerosis, chronic hepatitis,
pulmonary fibrosis and rheumatoid arthritis caused by the
activation of macrophages. Our results clearly demon-
strated that EEPC inhibited NO and PGE2 production via
the suppression of iNOS and COX-2 expression, respect-
ively, which appears to be due to the transcriptional sup-
pression of these genes (Figures 1 and 2).
The release of pro-inflammatory cytokines is elevated
predominantly by activated macrophages during pathogen
infection and they are involved in the up-regulation of in-
flammatory reactions. Of these cytokines, IL-1β is a potent
activator of immune responses directed against bacterial
infections. Abnormal IL-1β release changes the conditions
toward a pathological microenvironment, resulting either
in chronic inflammation or in the absence of a proper im-
mune surveillance against infections, respectively [6,35]. In
addition, inflammation is often associated with the over-
expression of TNF-α, which is a multi-functional cytokine
involved in the signaling pathways implicated in inflamma-
tion, immunity, cell survival, and even tumorigenesis. This
cytokine exhibits its pro-inflammatory activity by regulating
several intercellular and vascular cell-adhesion molecules,
resulting in the recruitment of leukocytes to sites of inflam-
mation [7,8]. Moreover, the production of TNF-α and IL-
1β is crucially required for the synergistic induction of NO
and PGE2 production in LPS-stimulated macrophages
[36,37]. Such findings suggest that the inhibition of these
cytokines’ production could be a useful approach as a treat-
ment strategy for various inflammatory diseases. In the
current investigation, the concentrations of TNF-α and
IL-1β were markedly increased after treatment with LPS
in RAW 264.7 macrophages; while pre-treatment with
EEPC significantly inhibited this effect in a concentration-
dependent manner (Figure 3). We also found that thesuppressive effect of EEPC on LPS-induced production of
TNF-α and IL-1β was mediated at the transcription level
(Figure 4). These findings provide evidence that EEPC
possesses potentially useful anti-inflammatory activities.
Of the several transcriptional factors activated by in-
flammatory responses during bacterial infections, NF-κB
plays a critical role in several signal transduction pathways.
Hence, agents that are able to inhibit NF-κB transcrip-
tional regulation and modulate the inflammatory response
may have therapeutic use, and there is a growing interest
among researchers in targeting the NF-κB signaling path-
way in the fight against inflammation [11,12]. In the ab-
sence of stimuli, in most cells, NF-κB is associated with
inhibitor proteins, IκBs, and as a result, NF-κB is retained
in the cytoplasm. However, when the cells are stimulated
with pro-inflammatory stimuli, IκBs are rapidly phosphor-
ylated, degraded, and thereby dissociated from NF-κB.
The resulting free NF-κB is then translocated into the nu-
cleus, where it binds to the κB elements and induces the
transcription of genes encoding pro-inflammatory media-
tors and cytokines [38,39]. Thus, we presumed that the
above inhibitory effect of EEPC on the LPS-induced over-
production of pro-inflammatory mediators and cytokines
involves the NF-κB signaling pathway; we next measured
the effects of EEPC on LPS-induced-NF-κB nuclear trans-
location. Western blotting, EMSA and immunofluores-
cence results revealed that EEPC inhibited the LPS-induced
degradation of IκB-α and the subsequent translocation of
the p65 subunit of NF-κB from the cytosol to the nucleus,
and markedly attenuated LPS-induced NF-κB binding
activity (Figures 5 and 6). These data indicated that the
anti-inflammatory effect of EEPC might be the result of the
inhibition of the degradation of IκB, and then a reduction
in NF-κB p65 translocation to the nucleus.Conclusions
In conclusion, our study demonstrated that EEPC is a po-
tent inhibitor of pro-inflammatory mediators and cytokines
in an LPS-stimulated RAW 264.7 murine macrophage cell
model via down-regulating the NF-κB signaling pathway to
attenuate their corresponding gene activations. Although
further studies are still needed, these findings provide a
partial molecular explanation for the anti-inflammatory
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